Table 2.
Biweekly therapy evolution in the hospitalized COVID-19 patients in Castile and Leon (Spain) during the first wave (1 March to 31 May 2020).
| Medicines | 1–14 March | 15–31 March | 1–14 April | 15–30 April | 1–14 May | 15–31 May |
|---|---|---|---|---|---|---|
| n = 117 | n = 2819 | n = 2155 | n = 1250 | n = 588 | n = 378 | |
| Antibiotics | 79.49 (72.17–86.8) | 91.63 (90.61–92.65) | 90.95 (89.74–92.16) | 91.6 (90.06–93.14) | 88.1 (85.48–90.71) | 89.42 (86.32–92.52) |
| Ceftriaxone | 47.01 (37.96–56.05) | 71.83 (70.17–73.49) | 68.45 (66.48–70.41) | 66.96 (64.35–69.57) | 69.73 (66.01–73.44) | 68.78 (64.11–73.45) |
| Azithromycin | 25.64 (17.73–33.55) | 70.95 (69.27–72.62) | 73.74 (71.88–75.59) | 67.28 (64.68–69.88) | 52.21 (48.17–56.25) | 52.12 (47.08–57.15) |
| Levofloxacin | 44.44 (35.44–53.45) | 16.42 (15.06–17.79) | 10.95 (9.63–12.27) | 15.52 (13.51–17.53) | 17.52 (14.44–20.59) | 17.72 (13.88–21.57) |
| Cefditoren | 0.85 (0.1–1.69) | 3.12 (2.48–3.76) | 2.55 (1.89–3.22) | 2.4 (1.55–3.25) | 2.04 (0.9–3.18) | 1.32 (0.17–2.47) |
| Teicoplanin | 2.56 (0.3–5.49) | 1.21 (0.8–1.61) | 1.62 (1.09–2.16) | 1.36 (0.72–2) | 1.19 (0.31–2.07) | 1.59 (0.33–2.85) |
| Clarithromycin | 0.85 (0.1–1.69) | 0.32 (0.11–0.53) | 0.19 (0–0.37) | 0.48 (0.1–0.86) | 0.34 (0.13–0.55) | 1.32 (0.17–2.47) |
| Cefotaxime | 1.71 (0.03–2.65) | 0.14 (0–0.28) | 0.23 (0.03–0.44) | 0.4 (0.05–0.75) | 0.51 (0.07–0.95) | 0.26 (0.05–0.58) |
| Moxifloxacin | 0 (0–0) | 0.18 (0.02–0.33) | 0.42 (0.15–0.69) | 0.24 (0.03–0.45) | 0.51 (0.07–0.95) | 0.26 (0.25–0.58) |
| Ceftaroline | 0 (0–0) | 0.11 (0.01–0.21) | 0 (0–0) | 0.08 (0.02–0.14) | 0 (0–0) | 0 (0–0) |
| Antimalarials | 42.74 (33.77–51.7) | 84.04 (82.68–85.39) | 76.29 (74.49–78.08) | 60 (57.28–62.72) | 32.14 (28.37–35.92) | 24.87 (20.51–29.23) |
| Hydroxycloroquine | 36.75 (28.02–45.49) | 76.48 (74.92–78.05) | 71.18 (69.27–73.1) | 58.96 (56.23–61.69) | 31.63 (27.87–35.39) | 23.81 (19.52–28.1) |
| Cloroquine | 6.84 (2.26–11.41) | 10.85 (9.71–12) | 5.15 (4.22–6.08) | 1.12 (0.54–1.7) | 0.51 (0.07–0.95) | 1.59 (0.33–2.85) |
| Steroids | 59.83 (50.95–68.71) | 44.45 (42.61–46.28) | 43.67 (41.57–45.76) | 44.72 (41.96–47.48) | 42.69 (38.69–46.68) | 44.44 (39.44–49.45) |
| Methylprednisolone | 56.41 (47.43–65.4) | 42.21 (40.39–44.04) | 40.23 (38.16–42.3) | 41.52 (38.79–44.25) | 37.59 (33.67–41.5) | 39.42 (34.49–44.34) |
| Prednisone | 11.11 (5.42–16.81) | 8.09 (7.08–9.09) | 10.12 (8.84–11.39) | 9.44 (7.82–11.06) | 11.56 (8.98–14.15) | 10.32 (7.25–13.38) |
| Antivirals | 38.46 (29.65–47.28) | 65.02 (63.01–66.43) | 42.51 (40.25–44.32) | 20.24 (18.01–22.47) | 8.5 (6.25–10.76) | 6.61 (4.11–9.12) |
| Lopinavir-Ritonavir | 38.46 (29.65–47.28) | 64.88 (63.12–66.64) | 42.37 (40.28–44.45) | 20.24 (18.01–22.47) | 8.5 (6.25–10.76) | 6.61 (4.11–9.12) |
| Remdesevir | 0 (0–0) | 0.14 (0–0.28) | 0.14 (0.02–0.26) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| Tocilizumab | 7.69 (2.86–12.52) | 13.2 (11.95–14.45) | 10.58 (9.28–11.88) | 4.8 (3.61–5.99) | 1.87 (0.78–2.97) | 1.32 (0.17–2.47) |
| Other Anti-SIRS | 15.38 (8.85–21.92) | 13.2 (11.95–14.45) | 5.06 (4.13–5.98) | 2.16 (1.35–2.97) | 1.02 (0.21–1.83) | 1.06 (0.03–2.09) |
| Interferon Beta | 15.38 (8.85–21.92) | 12.2 (10.99–13.41) | 2.18 (1.56–2.8) | 0 (0–0) | 0 (0–0) | 0.79 (0.1–1.67) |
| Anakinra | 0 (0–0) | 0.89 (0.54–1.23) | 2.51 (1.85–3.17) | 1.68 (0.97–2.39) | 0.17 (0.06–0.35) | 0.53 (0.2–1.22) |
| Baricitinib | 0 (0–0) | 0.11 (0.01–0.21) | 0.42 (0.15–0.69) | 0.64 (0.2–1.08) | 0.85 (0.11–1.59) | 0 (0–0) |
| Siltuximab | 0 (0–0) | 0.18 (0.02–0.33) | 0.23 (0.03–0.44) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| Ruxolitinib | 0 (0–0) | 0.11 (0.01–0.21) | 0.19 (0–0.37) | 0.08 (0.02–0.14) | 0 (0–0) | 0 (0–0) |
Abbreviations: 95% CI, confidence interval; SIRS, systemic inflammatory response syndrome.